Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Fintepla, fenfluramine, Date of authorisation: 18/12/2020, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Fintepla, fenfluramine, Date of authorisation: 18/12/2020, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Enzalutamide Viatris, enzalutamide, Date of authorisation: 22/08/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Enzalutamide Viatris, enzalutamide, Date of authorisation: 22/08/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Intuniv, guanfacine, Date of authorisation: 17/09/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Intuniv, guanfacine, Date of authorisation: 17/09/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Lynozyfic, linvoseltamab, Date of authorisation: 23/04/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Lynozyfic, linvoseltamab, Date of authorisation: 23/04/2025, Revision: 2, Status: Authorised

Unified application programming interface (API) platform event, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 December 2026, 10:00 (CET) to 2 December 2026, 12:00 (CET)

Unified application programming interface (API) platform event, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 December 2026, 10:00 (CET) to 2 December 2026, 12:00 (CET)

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 7, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.